University of Groningen
Renal heparan sulfate proteoglycans
Talsma, Ditmer Tjitze
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Talsma, D. T. (2018). Renal heparan sulfate proteoglycans: A double edged sword. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Stellingen
Behorende bij het proefschrift
Renal heparan sulfate proteoglycans
A double edged sword
1. Renal endothelial heparan sulfates are crucial in the early develop-ment of fibrosis in diabetic nephropathy.
2. Subendothelial heparan sulfate proteoglycans are as important as lu-minal heparan sulfate proteoglycans in leukocyte transmigration. 3. Chemokine-heparan sulfate interaction should be considered a
poten-tial target in inflammation mediated renal diseases.
4. Extensive interaction studies between heparan sulfates and chemo-kines/cytokines are necessary to exactly define binding epitope re-quirements of glycomimetics to limit unwanted interactions upon clinical application.
5. Tubular heparan sulfate is a ligand for properdin and causes properdin to be a pattern recognition molecule initiating the alternative comple-ment pathway.
6. Tick salivary protein Salp20 has great potential to form the base for new alternative pathway inhibitors.
7. MASP enzyme inhibiting heparin fragments can be a new entity in lec-tin pathway mediated renal disease.
8. As `t net kin sa`t it moat, dan moat it mar sa`t it kin. 9. Er bestaan geen feiten alleen interpretaties. (F. Nietzsche) 10. Twijfel is het begin van wijsheid. (R. Descartes)
11. Rijkdom bestaat niet uit het hebben van grote bezittingen, maar in het hebben van weinig behoeften. (Epicurus)
